Regional brain hypometabolism is unrelated to regional amyloid plaque burden

Brain

Volumn 138, Issue 12, 2015, Pages 3734-3746

  Altmann, Andre ^a   Ng, Bernard ^a   Landau, Susan M ^b   Jagust, William J ^b   Greicius, Michael D ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; amyloid imaging; glucose metabolism; positron emission tomography

Indexed keywords

AMYLOID; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR;

AGE; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; EDUCATION; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ATROPHY; BRAIN; CASE CONTROL STUDY; COGNITIVE DEFECT; METABOLISM; PATHOLOGY;

AGED; ANILINE COMPOUNDS; ATROPHY; BRAIN; CASE-CONTROL STUDIES; COGNITIVE DYSFUNCTION; ETHYLENE GLYCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROIMAGING; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY;

EID: 84950992864     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv278     Document Type: Article

References (62)

1. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimers disease. Neurology 1992; 42(3 Pt 1): 631-9.
2. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007; 38: 95-113.
3. Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005; 26: 839-51.
4. Ashburner J, Neelin P, Collins DL, Evans A, Friston K. Incorporating prior knowledge into image registration. Neuroimage 1997; 6: 344-52.
5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
6. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimers disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709-17.
7. Chetelat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimers disease. Neuroimage Clin 2013; 2: 356-65.
8. Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci 2009; 29: 14770-8.
9. Craddock RC, James GA, Holtzheimer PE, 3rd, Hu XP, Mayberg HS. A whole brain fMRI atlas generated via spatially constrained spectral clustering. Hum Brain Mapp 2012; 33: 1914-28.
10. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, et al. Evidence that the beta-amyloid plaques of Alzheimers disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 2000; 275: 19439-42.
11. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68: 501-8.
12. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimers disease. Brain 2006; 129 (Pt 11): 2856-66.
13. Forster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Forstl H, et al. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimers disease. Euro J Nucl Med Mol Imaging 2012; 39: 1927-36.
14. Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Nagren K, Rinne JO. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 2009; 72: 1504-11.
15. Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A, Racine C, et al. Cognition, glucose metabolism and amyloid burden in Alzheimers disease. Neurobiol Aging 2012; 33: 215-25.
16. Giannakopoulos P, Hof PR, Michel JP, Guimon J, Bouras C. Cerebral cortex pathology in aging and Alzheimers disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts. Brain Res Brain Res Rev 1997; 25: 217-45.
17. Gomez-Isla T, Growdon WB, McNamara MJ, Nochlin D, Bird TD, Arango JC, et al. The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimers disease brain: evidence for other phenotype-modifying factors. Brain 1999; 122 (Pt 9): 1709-19.
18. Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA 2003; 100: 253-8.
19. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimers disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 2004; 101: 4637-42.
20. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimers disease. Trends Pharmacol Sci 1991; 12: 383-8.
21. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
22. Hardy JA, Higgins GA. Alzheimers disease: the amyloid cascade hypothesis. Science 1992; 256: 184-5.
23. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999; 19: 8876-84.
24. Hatsuta H, Takao M, Ishii K, Ishiwata K, Saito Y, Kanemaru K, et al. Amyloid beta accumulation assessed with 11C-Pittsburgh compound B PET and postmortem neuropathology. Curr Alzheimer Res 2015; 12: 278-86.
25. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. ArchNeurol 2011; 68: 1062-4.
26. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimers disease. Brain 2008; 131Pt 6): 1630-45.
27. Jack CR, Jr., Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimers disease and amnestic mild cognitive impairment. Brain 2008; 131 (Pt 3): 665-80.
28. Jack CR, Jr., Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol 2014; 13: 997-1005.
29. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimers Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010; 6: 221-9.
30. Jagust WJ, Landau SM, Alzheimers Disease Neuroimaging I. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 2012; 32: 18227-33.
31. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006; 67: 1575-80.
32. Koch K, Myers NE, Gottler J, Pasquini L, Grimmer T, Forster S, et al. Disrupted intrinsic networks link amyloid-beta pathology and impaired cognition in prodromal Alzheimers disease. Cereb Cortex 2014. Advance Access published on July 4, 2014, doi: 10.1093/cercor/bhu151.
33. La Joie R, Perrotin A, Barre L, Hommet C, Mezenge F, Ibazizene M, et al. Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimers disease dementia. J Neurosci 2012; 32: 16265-73.
34. Laforce R, Jr.,Tosun D, Ghosh P, Lehmann M, Madison CM, Weiner MW, et al. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimers pathology. Neuroimage Clin 2014; 4: 508-16.
35. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-53.
36. Landman BA, Huang AJ, Gifford A, Vikram DS, Lim IA, Farrell JA, et al. Multi-parametric neuroimaging reproducibility: a 3-T resource study. Neuroimage 2011; 54: 2854-66.
37. Lee HG, Casadesus G, Zhu X, Takeda A, Perry G, Smith MA. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci 2004; 1019: 1-4.
38. Lehmann M, Ghosh PM, Madison C, Laforce R, Jr., Corbetta-Rastelli C, Weiner MW, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimers disease. Brain 2013; 136 (Pt 3): 844-58.
39. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimers disease. Euro J Nucl Med Mol Imaging 2008; 35: 2169-81.
40. Lowe VJ, Weigand SD, Senjem ML, Vemuri P, Jordan L, Kantarci K, et al. Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology 2014; 82: 1959-67.
41. Michel V, Gramfort A, Varoquaux G, Eger E, Keribin C, Thirion B. A supervised clustering approach for fMRI-based inference of brain states. Pattern Recognit 2012; 45: 2041-9.
42. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73: 754-60.
43. Poisnel G, Herard AS, El Tannir El Tayara N, Bourrin E, Volk A, Kober F, et al. Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimers disease. Neurobiol aging 2012; 33: 1995-2005.
44. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimers disease. Neurobiol Aging 1991; 12: 295-312.
45. Rabinovici GD, Furst AJ, Alkalay A, Racine CA, ONeil JP, Janabi M, et al. Increased metabolic vulnerability in early-onset Alzheimers disease is not related to amyloid burden. Brain 2010; 133 (Pt 2): 512-28.
46. Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008; 64: 388-401.
47. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci USA 2001; 98: 676-82.
48. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275-83.
49. Saint-Aubert L, Nemmi F, Peran P, Barbeau EJ, Payoux P, Chollet F, et al. Comparison between PET template-based method and MRI based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Euro J Nucl Med Mol Imaging 2014; 41: 836-43.
50. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimers disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimers disease. Nat Med 1996; 2: 864-70.
51. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009; 62: 42-52.
52. Sepulcre J, Sabuncu MR, Becker A, Sperling R, Johnson KA. In vivo characterization of the early states of the amyloid-beta network. Brain 2013; 136 (Pt 7): 2239-52.
53. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimers disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-13.
54. Shirer WR, Ryali S, Rykhlevskaia E, Menon V, Greicius MD. Decoding subject-driven cognitive states with whole-brain connectivity patterns. Cereb Cortex 2012; 22: 158-65.
55. Sorg C, Riedl V, Muhlau M, Calhoun VD, Eichele T, Laer L, et al. Selective changes of resting-state networks in individuals at risk for Alzheimers disease. Proc Natl Acad Sci USA 2007; 104: 18760-5.
56. Sperling RA, Laviolette PS, OKeefe K, OBrien J, Rentz DM, Pihlajamaki M, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009; 63: 178-88.
57. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Jr.Eckman C, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994; 264: 1336-40.
58. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-89.
59. Van Essen DC, Ugurbil K. The future of the human connectome. Neuroimage 2012; 62: 1299-310.
60. Villemagne VL, Okamura N. In vivo tau imaging: obstacles and progress. Alzheimers Dement 2014; 10: 3 SupplS254-64.
61. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69: 181-92.
62. Wolfe KJ, Cyr DM. Amyloid in neurodegenerative diseases: friend or foe? Semin Cell Dev Biol 2011; 22: 476-81.